

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
9287ZYA

In Re Application Of **W. L. Masters et al.**

Serial No. **10/716,924**

Filing Date
November 19, 2003

Examiner
Unassigned

Group Art Unit
Unassigned

Title: **A METHOD FOR TREATING ALZHEIMER'S DISEASE**

Address to:

**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**(Under 37 CFR 1.97(b) r 1.97(c))**

Docket No.

9287ZYA

In Re Application: Colin L. Masters et al.

Serial No.

10/716,924

Filing Date

November 19, 2003

Examiner

Unassigned

Group Art Unit


Unassigned

A METHOD FOR TREATING ALZHEIMER'S DISEASE**Payment of Fee**


(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **19-1013/SSMP** as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:	
_____ (Date)	
_____ Signature	
_____ Typed or Printed Name of Person Signing Certificate	

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on 12/12/03 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
_____ Signature	
_____ Typed or Printed Name	

*This certificate may only be used if paying by deposit account.



Signature

Dated: December 12, 2003

Frank S. DiGiglio
Registration No. 31,346
Scully, Scott, Murphy & Presser
400 Garden City Plaza
Garden City, New York 11530

(516) 742-4343

cc: FSD:ab



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Colin L. Masters et al.

Examiner: Unassigned

Serial No.: 10/716,924

Art Unit: Unassigned

Filed: November 19, 2003

Docket: 9287ZYA

For: A METHOD FOR TREATING
ALZHEIMER'S DISEASE

Dated: December 12, 2003

Commissioner for Patents
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following references, which are listed on the attached Form PTO-1449, be made of record in the above-identified case.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on December 12, 2003.

Dated: December 12, 2003


Frank S. DiGiglio

Pursuant to 37 C.F.R. §1.98(d), copies of the listed documents on the attached PTO 1449 were previously submitted in prior applications, U.S. Serial Number 09/624,965, filed July 25, 2000, which is a continuation of U.S. Serial Number 08/757,537, filed November 27, 1996, now abandoned, which is a continuation of U.S. Serial Number 08/240,720, filed September 16, 1994, now U.S. Patent 5,705,401 issued January 6, 1998. Reference Numbers 74-79 were cited by the Examiner in connection with the parent case, U.S. Serial Number 09/624,965 therefore, copies of these references are not provided.

Consideration of this Information Disclosure Statement is respectfully requested, since the art provided may be material to the examination of the present application as filed under 37 C.F.R. §1.56.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R §1.97(b), no statement or fee is required.

Respectfully submitted,



Frank S. DiGiglio
Registration No. 31,346

SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343

XZ:ab



INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Atty. Docket No.	9287ZYA	Serial No.	10/716,924
Applicant	Colin Louis MASTERS et al.		
Filing Date	November 19, 2003.	Group:	Unassigned

U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	<u>1</u>	EP 0 613 560	10/21/98	Europe			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
<u>2</u>	Constantinidis, J., Hypothesis Regarding Amyloid and Zinc in the Pathogenesis of Alzheimer Disease: Potential for Preventive Intervention, <i>Alzheimer Disease and Associated Disorders</i> , Vol. 5, No. 1, pp. 31-35 (1991).
<u>3</u>	McLachlan, D.R.C. et al., Intramuscular Desferrioxamine in Patients with Alzheimer's Disease, <i>The Lancet</i> , Vol. 337, pp. 1304-1308 (1991).
<u>4</u>	Kruck, T.P.A. et al., Suppression of Deferoxamine Mesylate Treatment - Induced Side Effects by Coadministration of Isoniazid in a Patient with Alzheimer's Disease Subject to Aluminum Removal by Ionspecific Chelation, <i>Clinical Pharmacol. Ther.</i> , pp. 439-446 (1990).
<u>5</u>	Cardelli, M.B. et al., Chelation Therapy - Unproved Modality in the Treatment of Alzheimer -Type Dementia, <i>Journal of the American Geriatrics Society</i> , Vol. 33, No. 8, pp. 548-551 (1985).
<u>6</u>	Domingo, José L. et al., The Use of Chelating Agents in the Treatment of Aluminum Overload, <i>Clinical Toxicology</i> , Vol. 27, No. 6, pp. 355-367 (1989).

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce



INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Atty. Docket No.	9287ZYA	Serial No.	10/716,924
Applicant	Colin Louis MASTERS et al.		
Filing Date	November 19, 2003	Group:	Unassigned

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate


FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

7.	Yokel, R.A. et al., Evaluation of Potential Aluminum Chelators <i>in Vitro</i> by Aluminum Solubilization Ability, Aluminum Mobilization from Transferrin and the Octanol/Aqueous Distribution of the Chelators and Their Complexes with Aluminum, <i>The Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 257, No. 1, pp. 100-106 (1991).
8.	Olivieri, N.F. et al., Comparison of Oral Iron Chelator L1 and Desferrioxamine in Iron-Loaded Patients, <i>The Lancet</i> , Vol. 336, pp. 1275-1279 (1990).
9.	Graf, E. et al., Effects of phytate on mineral bioavailability in mice, <i>J. Nutr.</i> , Vol. 114, No. 7, pp. 1192-1198 (1984) (abstract).
10.	Sandstrom, B., et al., Effect of Inositol Hexaphosphate on Retention of Zinc and Calcium from the Human Colon, <i>Eur J Clin Nutr</i> , Vol. 44, No. 10, pp. 705-708 (1990) (abstract).
11.	Walsh, C.T. et al., Zinc: Health Effects and Research Priorities for the 1990s, <i>Environmental Health Perspectives</i> , Vol. 102 (Suppl. 2), pp. 5-46 (1994).

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce



INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Atty. Docket No. 287ZYA	Serial No. 10/716,924
Applicant Colin Louis MASTERS et al.	
Filing Date November 19, 2003	Group: Unassigned

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

12.	Doll, Sir R., Review: Alzheimer's Disease and Environmental Aluminium, <i>Age and Ageing</i> , Vol. 22, pp. 138-153 (1993).
13.	Underwood, E.J., Trace Elements in Human and Animal Nutrition, 4 th Ed., Academic Press, NY 1977, pp. 196-242.

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce



INFORMATION DISCLOSURE CITATION

Atty. Docket No.	9287ZYA	Serial No.	10/716,924
Applicant Colin Louis MASTERS et al.			
Filing Date	November 19, 2003		Group: Unassigned

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
14.	4,281,061	07/28/81	Zuk et al.			
15.	4,419,365	12/06/83	McLachlan			
16.	4,847,082	07/11/89	Sabin			
17.	5,234,814	08/10/93	Card et al.			
18.	5,705,401	01/06/98	Masters et al.			

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
19.	AU-B-58173/90	01/07/91	Australia			
20.	AU-B-33365/89	11/02/89	Australia			
21.	WO91/16628	10/31/91	PCT			
22.	WO92/00521	01/09/92	PCT			
23.	WO92/13069	08/06/92	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

24.	Selkoe, et al., "β-Amyloid Precursor Protein of Alzheimer Disease Occurs as 110- to 135-Kilodalton Membrane-Associated Proteins in Neural and Non-Neural Tissues", <i>Proc. Natl. Acad. Sci.</i> , 85:7341-7345 (1988).
25.	Bush, A.I. et al. "The Amyloid Precursor of Alzheimer's Disease is Released by Human Platelets" <i>The Journal of Biological Chemistry</i> , 265 (26): 15977-19583 (1990).
26.	Bush, A.I. et al., Chapter 70 in K. Iqbal et al. (eds.) "Circulating Forms of Amyloid" <i>Alzheimer's Disease: Basic Mechanisms, Diagnosis and Therapeutic Strategies</i> , John Wiley & Sons, Chichester (1991).

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce



INFORMATION DISCLOSURE CITATION

Atty. Docket No.	92872YA	Serial No.	10/716,924
Applicant Colin Louis MASTERS et al.			
Filing Date	November 19, 2003	Group:	Unassigned

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
27.	JP04252954A	09/08/92	Japan (abstract)			
28.	JP04252955A	09/08/92	Japan (abstract)			
29.	JP04252956A	09/08/92	Japan (abstract)			
30.	JP04126095A	04/27/92	Japan (abstract)			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

31.	Bush., A.I. et al. "An Abnormality of Plasma Amyloid Protein Precursor in Alzheimer's Disease", <i>Annals of Neurology</i> 32 (1): 57-65 (1992).
32.	Cole, G.M. et al., "Stimulated Platelets Release Amyloid Beta-Protein Precursor", <i>Biochemical and Biophysical Research Communication</i> 170 (1): 288-295 (1990).
33.	Davies, L. et al., "A4 Amyloid Protein Deposition and the Diagnosis of Alzheimer's Disease: Prevalence in Aged Brains Determined by Immunocytochemistry Compared With Conventional Neuropathologic Techniques", <i>Neurology</i> 38 (11): 1688-1693 (1988).
34.	Davies, I.J.T. et al., "Measurements of Plasma Zinc", <i>J. Clin. Path.</i> 21: 359-365 (1968).
35.	Esch, F.S. et al., "Cleavage of Amyloid Peptide β During Constitutive Processing of Its Precursor", <i>Science</i> 248: 1122-1124 (1990).
36.	Folstein, M.F. et al. "'Mini-mental State' A Practical Method for Grading the Cognitive State of Patients for the Clinician", <i>J. Psychiat. Res.</i> 12: 189-198 (1975).

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce



INFORMATION DISCLOSURE CITATION

Atty. Docket No. 928721A	Serial No. 10/716,924
Applicant Colin Louis MASTERS et al.	
Filing Date November 19, 2003	Group: Unassigned

U.S. PATENT DOCUMENTS

Examiner Initial*		Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate


FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Sub Class	Translation Y s or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

37.	Palmert, M.R. et al., "The β -Amyloid Protein Precursor of Alzheimer Disease Has Soluble Derivatives Found in Human Brain and Cerebrospinal Fluid", <i>Proc. Natl. Acad. Sci USA</i> 86: 6338-6342 (1989).
38.	Podlisny, M.B. et al., "Detection of Soluble Forms of the β -Amyloid Precursor Protein in Human Plasma", <i>Biochemical and Biophysical Research Communications</i> 167 (3): 1094-1101 (1990).
39.	Rosa, J.P. et al., "Gray Platelet Syndrome: Demonstration of Alpha Granule Membranes That Can Fuse With the Cell Surface", <i>J. Clin. Invest.</i> 80: 1138-1146 (1987).
40.	Rumble, B. et al., "Amyloid A4 Protein and its Precursor in Down's Syndrome and Alzheimer's Disease", <i>New England Journal of Medicine</i> 320: 144-1452 (1989).
41.	Sisodia, S.S. et al., "Evidence That β -Amyloid Protein in Alzheimer's Disease is Not Derived by Normal Processing", <i>Science</i> 248: 492-495 (1990).
42.	Smith, P.K. et al., "Measurement of Protein Using Bicinchoninic Acid", <i>Analytical Biochemistry</i> 150: 76-85 (1985).
43.	Stanton, R., "Dietary Sources of Essential Minerals", <i>Australian Prescriber</i> 15 (2): 36-38 (1992).
44.	Weidemann, A. et al., "Identification, Biogenesis and Localization of Precursors of Alzheimer's Disease A4 Amyloid Protein", <i>Cell</i> 57: 115-126 (1989).

Examiner	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce



INFORMATION DISCLOSURE CITATION

Atty. Docket No. 287ZYA	Serial No. 10/716,924
Applicant Colin Louis MASTERS et al.	
Filing Date November 19, 2003	Group: Unassigned

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate


FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes r No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

45.	Wessel, D. and Flügge, U.I., "A Method for the Quantitative Recovery of Protein in Dilute Solution in the Presence of Detergents and Lipids", <i>Analytical Biochemistry</i> 138: 141-143 (1984).
46.	Zubenko, G.S. et al., "Platelet Membrane Abnormality in Alzheimer's Disease", <i>Annals of Neurology</i> 22: 237-244 (1987).
47.	Anderton, B.H., "Alzheimer's Disease: Progress in Molecular Pathology", <i>Nature</i> 325: 658-659 (1987).
48.	Huang, X.D. et al., "Zinc-induced Alzheimer's A-Beta-1-40 Aggregation is Mediated by Conformational Factors", <i>J. Biol. Chem.</i> 272: 26464-26470 (1997).
49.	Mok, S.S. et al., "A Novel Metalloprotease in Rat Brain Cleaves the Amyloid Precursor Protein of Alzheimer's Disease Generating Amyloidogenic Fragments", <i>Biochemistry</i> 36: 156-163 (1997).
50.	Whyte, S. et al., Chapter 54 in K. Iqbal et al. (eds.) "the Metabolism of the Amyloid . . .", <i>Alzheimer's Disease: Biology, Diagnosis . . .</i> , John Wiley and Sons, Chichester (1997).
51.	Multhaup, G. et al., Chapter 67 in K. Iqbal et al. (eds.), "The Amyloid Precursor Protein . . .", <i>Alzheimer's Disease: Biology, Diagnosis and Therapeutic . . .</i> , John Wiley and Sons, Chichester (1997).
52.	Li, Q.X et al., "Proteolytic Processing of Alzheimer's Disease A4 Amyloid Precursor Protein in Human Platelets", <i>The Journal of Biological Chemistry</i> 270 (23): 14140-14147 (1995).

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce



INFORMATION DISCLOSURE CITATION

Atty. Docket No. 287ZYA	Serial No. 10/716,924
Applicant Colin Louis MASTERS et al.	
Filing Date November 19, 2003	Group: Unassigned

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate


FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

53.	Goldgaber, D. et al., "Characterization and Chromosomal Localization of a cDNA Encoding Brain Amyloid of Alzheimer's Disease", <i>Science</i> 235: 877-880 (1987).
54.	Hider, R.C. et al., "Facilitated Uptake of Zinc into Human Erythrocytes", <i>Biochemical Pharmacology</i> 39 (6): 1005-1012 (1990).
55.	Kang, J. et al., "The Precursor of Alzheimer's Disease Amyloid A4 Protein Resembles a Cell-Surface Receptor", <i>Nature</i> 325: 733-736 (1987).
56.	McKhann, G. et al., "Clinical Diagnosis of Alzheimer's Disease: Report of the NINCDS-ADRDA Work Group Under the Auspices of Department of Health and Human Services Task Force on Alzheimer's Disease", <i>Neurology</i> 34: 939-944 (1984).
57.	Moir, R.D. et al., "Human Brain β A4 Amyloid Protein Precursor of Alzheimer's Disease: Purification and Partial Characterization", <i>Journal of Neurochemistry</i> 59 (4): 1490-1498 (1992).
58.	Mönning, U. et al., "Synthesis and Secretion of Alzheimer Amyloid β A4 Precursor Protein By Stimulated Human Peripheral Blood Leucocytes", <i>FEBS Letters</i> 277 (1)(2): 261-266 (1990).
59.	Multhaup, G. and Mechler, H., "Characterization of the High Affinity Heparin Binding Site . . .", <i>Journal of Molecular Recognition</i> 8: 247-257 (1995).

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce



INFORMATION DISCLOSURE CITATION

Atty. Docket No.	9287ZYA	Serial No.	10/716,924
Applicant	Colin Louis MASTERS et al.		
Filing Date	November 19, 2003	Group:	Unassigned

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate


FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Y s r No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

60.	Multhaup, G. et al., "The Amyloid Precursor Protein of Alzheimer's Disease in the Reduction of Copper (I)", <i>Science</i> 271: 1406-1509 (1996).
61.	Whyte, S., "Aspects of the Biochemistry of the Amyloid Precursor Protein of Alzheimer's Disease, abstract of Ph.D. Dissertation presented to Dept. of Pathology, University of Melbourne, Australia (1997).
62.	Fuller, S., "Chapter 3: The Effects of A13+, Zn2+ and Cu2+ ions on the Metabolism of APP in PC1 Cells", Ph.D. Dissertation (1998).
63.	Morris et al., "The Consortium to Establishing a Registry for Alzheimer's Disease", <i>Neurology</i> , 39: 1159-1165 (1989).
64.	Barinaga, M., <i>Science</i> 264: 772-774 (1994).
65.	Shrine, <i>BioWorld Today</i> , 5(123): 1.
66.	Godert et al., <i>Current Opinion in Neurobiology</i> 1: 441-447 (1991).

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce



INFORMATION DISCLOSURE CITATION

Atty. Docket No.	9287ZYA	Serial No.	10/716,924
Applicant	Colin Louis MASTERS et al.		
Filing Date	November 19, 2003	Group:	Unassigned

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate


FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

67.	Cuajangco et al., <i>Brain Research Reviews</i> 23(2): 219-236 (1997).
68.	Borman, S., <i>Science</i> , 33-34 (June 17, 1996).
69.	Kruck et al., <i>Clinical Pharmacology and Therapeutics</i> 48(4): 439-446 (1990).
70.	Smedman et al., <i>Molecular and Chemical Neuropathology</i> 31(1): 13-28 (1997).
71.	Constantinidis et al., <i>Drug Dev. Res.</i> 27(1): 1-14 (1992).
72.	Chong et al., <i>Life Sciences</i> 59(7): 545-557 (1996).
73.	Matic et al., <i>Neurochem Int.</i> 30(b): 543-548 (1997).

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce



INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Atty. Docket No.	9287ZYA	Serial No.	10/716,924
Applicant	Colin Louis MASTERS et al.		
Filing Date	November 19, 2003	Group:	Unassigned

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes r No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

74.	Prajapati et al., 1991, J. Ed. Sci. Technol., 28,4,pp.204-7
75.	Powers et al., 1-90, Eur. J. Appl. Physiol., 60, pp.54-60
76.	Council et al., 1991, Current Opinion in Neurobiology, 1,pp.441-7
77.	Pratico et al., 2001, J. Neurosci, 21, No. 12, pp. 4183-4187
78.	Clark et al., 1996, The Dementias, London-Academic, pp. 285-304
79.	Cardelli et al. Unproved Modality inthe Treatment of Alzheimer- Type Dementia. J. Am. Geriatr. Soc., 1985, 33, pp.548-561

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce